EVIDENCE OF ENHANCEMENT OF THE RAS ONCOGENE PROTEIN PRODUCT (P21) IN A SPECTRUM OF HUMAN-TUMORS
EVIDENCE OF ENHANCEMENT OF THE RAS ONCOGENE PROTEIN PRODUCT (P21) IN A SPECTRUM OF HUMAN-TUMORS
复制标题
DOI：
10.1002/ijc.2910430315
复制
发表时间：
1989-03-15
影响因子：
6.4
通讯作者：
HAND, PH
中科院分区：
文献类型：
--
作者：
DEBIASI, F;DELSAL, G;HAND, PH
采用直接结合液体竞争放射免疫测定法，定量测定了ras癌基因蛋白产物p21在多种人类肿瘤和邻近表面正常组织中的含量。在50例患者的50例匹配的肿瘤和正常组织活检标本中，48例肿瘤中检测到的erasp21比正常组织中检测到的更多。28例乳腺肿瘤中有25例显示比纤维腺瘤的平均值更高。此外，在研究的19例病例中，有17例在乳腺癌中观察到的asp21比正常病例多20%以上。Morerasp21在胃、肺、结肠和膀胱的大多数肿瘤中也表现出来，与它们各自相邻的正常组织相比。因此，我们的数据表明，在起源于几种不同组织类型的许多人类肿瘤中，rasp21的表达在数量上增强。
Using a direct binding liquid competition radioimmunoassay, the amount of the ras oncogene protein product, p21, was quantitated in a variety of human tumors and adjacent apparently normal tissues. In 48 of 50 matched tumor and normal tissue biopsy specimens from 50 patients, morerasp21 was detected in the tumor than in its normal counterpart. Twenty‐five of 28 breast tumors demonstrated morerasp21 than the average of the values obtained for fibroadenomas. Furthermore, in 17 of the 19 cases studied, over 20% morerasp21 was observed in breast carcinomas compared with their respective normal counterparts. Morerasp21 was also demonstrated in the majority of tumors of the stomach, lung, colon and bladder compared with their respective adjacent normal tissues. Our data therefore indicate thatrasp21 expression is quantitatively enhanced in many human tumors originating from several different tissue types.